The license covers patents, patent applications, intellectual property, data and certain other assets relating to novel inhibitors of cortisol synthesis.
Included within the licensed assets is an issued patent which broadly covers the field of cortisol synthesis inhibition for treatment of metabolic diseases such as type 2 diabetes and metabolic syndrome.
“We are very excited at the prospect of being the first company to bring a cortisol synthesis inhibitor (CSI) to market. Many of the big pharma companies are in hot pursuit of this target,” commented Daniel Green, president of DiObex. “There are convincing data supporting the thesis that elevated cortisol activity is one of the leading causes of insulin resistance, visceral fat deposition, dyslipidemias, elevated cholesterol and blood pressure.”